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Abstract
Background: Ophthalmic viscosurgical devices (OVDs) are widely used in phacoemulsification cataract surgery to
maintain adequate intraocular space, stabilize ocular tissue during the operation and decrease the possible damage
of the corneal endothelium. Our study has the purpose to compare the corneal and foveal changes of Viscoat and
Visthesia in patients undergoing uneventful phacoemulsification cataract surgery.
Methods: Participants in our study were 77 consecutive patients, who were randomized into two groups based on
type of OVD used during phacoemulsification: Viscoat or Visthesia. All patients underwent a complete
ophthalmological examination i.e., measurement of best corrected visual acuity (BCVA) by means of Snellen charts,
intraocular pressure examination by Goldmann tonometry, slit lamp examination, fundus examination, optical
coherence tomography, specular microscopy and ultrasound pachymetry preoperatively and at three time points
postoperatively (day 3, 15, 28 postoperatively). The differences in baseline characteristics, as well as in outcomes
between the two groups were compared by Mann-Whitney-Wilcoxon test and Student’s t-test, as appropriate.
Results: Intraoperatively, there was no statistically significant difference in the duration of the ultrasound
application between the two groups, while Viscoat group needed more time for the operation performance. It is
also worthy to mention that Visthesia group exhibited less intense pain than patients in Viscoat group.
Postoperatively, there was a statistically significant difference in central corneal thickness, endothelial cell count and
macular thickness between the two groups, but BCVA (logMAR) did not differ between the two groups.
Conclusions: Our study suggests that Viscoat is more safe and protective for the corneal endothelium during
uneventful phacoemulsification cataract surgery, while Visthesia is in superior position regarding intraoperative pain.
Patients of both groups acquired excellent visual acuity postoperative. Finally, this is the first study comparing
OVDs in terms of macular thickness, finding that Visthesia cause a greater increase in macular thickness
postoperatively than Viscoat, although it reaches normal ranges in both groups.
Background
Ophthalmic viscosurgical devices (OVDs) in cataract
surgery were first described by Balazs et al. in 1972 [1].
Since then they are widely used in phacoemulsification
cataract surgery. Specifically, OVDs maintain adequate
intraocular space and stabilize ocular tissue during the
operation, especially in the stages of capsulorhexis and
intraocular lens (IOL) implantation [2-9]. Moreover,
OVDs facilitate any surgical manoeuvres and decrease
the possible damage of the corneal endothelium due to
surgical trauma [2,3,6]. They are also considered to inhi-
bit the formation of free radicals which negatively affect
the corneal endothelium during phacoemulsification
[2,10,11].
According to Arshinoff classification, OVDs can be
divided into two groups, based on their physicochemical
and rheological properties: dispersive and cohesive [12].
Dispersive OVDs have lower molecular weight, shorter
molecular chains and remain in the anterior chamber
more than cohesive OVDs, requiring a longer aspiration
time for their complete removal. In contrast, cohesive
OVDs help sustain the anterior chamber and can be
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Viscoat
®, a combination of sodium hyaluronate 3% and
chondroitin sulfate 4%, has the typical properties of a
dispersive OVD, while Visthesia
® Intracameral, a
formulation of sodium hyaluronate 1.5% and lidocaine
hydrochloride 1%, demonstrates as a cohesive one [7-9].
The characteristics of the two products are shown in
Table 1. It is worth mentioning that the mixture of an
OVD with an anaesthetic (viscoanaesthesia) may provide
more comfort to patients and makes the application of
the anaesthetic easy. However, the addition of lidocaine
in classic OVDs may prolong the toxic effect of lido-
caine on the corneal endothelium [9,13].
Under the light of the above, our study has the pur-
pose to compare the effect of Viscoat and Visthesia on
central corneal thickness, endothelial cell density, macu-
lar thickness and best corrected visual acuity (BCVA)
preoperatively and at three time points postoperatively
(day 3, 15, 28 postoperatively) in patients undergoing
uneventful phacoemulsification cataract surgery. Also,
intraoperative pain was evaluated.
Methods
Recruitment of patients, preoperative assessment,
randomization and exclusion criteria
Participants in our study were 77 consecutive patients,
who were recruited in the 1
st Department of Ophthal-
mology, University of Athens, Athens, Greece. Patients’
information included age, sex and which eye would be
operated. All eyes were the first to be operated, in order
to avoid heterogeneity. Preoperatively, all patients
underwent a complete ophthalmological examination i.
e., measurement of BCVA by means of Snellen charts,
intraocular pressure evaluation (IOP) by Goldmann
tonometry, slit lamp examination and fundus examina-
tion. Also, optical coherence tomography (OCT) exami-
nation (Stratus OCT3, Carl Zeiss Meditec, Dublin, CA,
USA) and specular microscopy (CSO SP-01 specular
miscoscope) were performed by an experienced opera-
tor, to measure macular thickness and endothelial cell
count (ECC) respectively. Furthermore, central corneal
thickness (CCT) was measured by ultrasound pachyme-
try using the Ocuscan
® RxP Alcon
®. After the preopera-
tive examination, patients were randomized into two
groups based on type of OVD used during phacoemulsi-
fication: Viscoat or Visthesia.
Exclusion criteria were corneal abnormalities, history
of intraocular surgery, preoperative endothelial cell
count less than 1500 cells/mm
2, history of uveitis, dia-
betes, age-related macular degeneration and intraopera-
tive complications, such as posterior capsule rupture,
vitreous loss, lost nucleus, zonule dehiscence and wound
leak. Moreover, one patient who developed cystoid
macular edema confirmed by OCT was excluded,
because he exhibited posterior capsule rupture during
the operation and we included only the uneventful cases
in our study.
The study was in accordance with the tenets of the
Declaration of Helsinki and has been approved by the
institutional review board of our hospital ("G. Gennima-
tas” Athens General Hospital). Written informed con-
sent was obtained from all patients.
Description of the procedure
On the day of surgery, the pupil was dilated with Tropi-
camide 0.5% (Tropixal, Demo) and Phenylephrine
Hydrochloride 5% (Phenylephrine, Cooper) drops every
10 minutes for 30 minutes before surgery. All operations
were performed with a standard technique by the same
surgeon. The lid and the periorbital skin were cleaned
and the conjunctival cul-de-sac was irrigated with povi-
done iodine. Proparacaine hydrochloride 0.5% drops
(Alcaine
®, Alcon laboratories) were used as topical anes-
thetic and were administered 10 minutes prior to the
beginning of surgery. The lid and the periorbital skin
were then draped and an open wide speculum was
placed. The eye was irrigated with Balanced Salt Solu-
tion (BSS
®, Alcon).
A clear corneal incision and side-port paracentesis
were made. OVD, either Viscoat or Visthesia, was
injected into the anterior segment and a continuous cur-
vilinear capsulorrhexis was created with a forceps. The
lens nucleus and cortex were hydrodissected with BSS.
This was followed by phacoemulsification, irrigation and
aspiration of cortical remnants via phaco chops methods
by using Infinity™ Vision System (Alcon Laboratories).
OVD infusion and implantation of the foldable posterior
chamber IOL were performed using the injector system
recommended for each lens. The viscoelastic material
was subsequently removed and surgical wounds were
hydrated with BSS. No sutures were applied. All wounds
were checked for leakage and found to be watertight.
The duration of the application of ultrasound during
phacoemulsification and the duration of the whole
operation were recorded. Immediately after the
Table 1 Physicochemical and rheological properties of
Viscoat and Visthesia
Property Viscoat
®
Visthesia
®
Manufacturer Alcon Laboratories Zeiss
Ingredients CDS/NaHa NaHa/LH
Concentration (%) 4 CDS/3 NaHa 1.5 NaHa/1 LH
Viscosity (mPas) 40000 500000
Molecular weight (Dalton) 22500 CDS/>500000 NaHa 3000000
Osmolarity (mOsm/L) 330 280-330
pH value 7-7.5 7-7.4
NaHa = sodium hyaluronate; CDS = chondroitin sulfate; LH = lidocaine
hydrochloride
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pain on a visual analog scale (VAS, range: 0-10). In spe-
cific, for VAS rating, we used a vertical line of 10 cm
length. One (bottom) end of the line was marked as
zero pain and the other (top) end of the line was
marked as maximum pain. After instructing patients
that the bottom end of the line represents no pain and
severity of pain increases as you go along the line and
reaches maximum pain at the top of the line, patients
were asked to mark the point in the line which repre-
sented the severity of their current pain. Then distance
from the bottom end of the line to the point marked by
the patients was measured in millimeters and the value
was taken as the pain score.
Postoperative treatment, follow-up
All patients received the same postoperative treatment i.
e., combination of tobramycin 0.3% - dexamethasone
0.1% (TobraDex
®, Alcon) one drop four times/day, plus
dorzolamide hydrochloride 2% - timolol maleate 0.5%
(Cosopt
®, Merck & Co) one drop twice/day. The topical
treatment was administered for 28 days after
phacoemulsification.
Three follow-up visits were scheduled for all patients:
on postoperative day 3, 15 and 28. A thorough ophthal-
mological examination, including BCVA measurement,
slit lamp examination, IOP measurement, fundoscopy,
OCT scan, ECC measurement and CCT measurement,
was performed in all follow-up visits by the same
ophthalmologist.
Statistical analysis
The Gaussian distribution assumption was tested using
the Kolmogorov - Smirnov test. None of variables
(BCVA, ECC, CCT, macular thickness, ultrasound
duration, intraoperative pain) succeeded in passing the
normality test, except for age and total operation
duration.
The differences in baseline characteristics, as well as in
outcomes between the two groups were compared by
Mann-Whitney-Wilcoxon test for independent samples
(referred to as MWW for reasons of brevity), as appro-
priate. Given that four comparisons (day 0, 3, 15, 28)
took place, the Bonferroni correction for multiple com-
parisons was adopted; as a result the threshold of statis-
tical significance for p values was set to 0.05/4 = 0.0125.
Concerning BCVA, the descriptive statistics of the log of
t h em i n i m u ma n g l eo fr e s o l u t i o n( l o g M A R )w e r ec o m -
puted as appropriate [14].
The Student t-test was used to compare age and total
operation duration between the two groups, because
they followed the normal distribution. Statistical analysis
was performed with STATA 10.0 statistical software
(StataCorp, College Station, TX, USA).
Results
The demographic and intraoperative characteristics of
t h et w og r o u p sa r es h o w ni nT a b l e2 .T h e r ew e r en o
statistically significant differences between groups preo-
peratively in age, gender, BCVA, ECC, CCT and macu-
lar thickness. Intraoperatively, there was no statistically
significant difference in the duration of the ultrasound
application between the two groups (p = 0.483, MWW
test), while Viscoat group needed more time for the
operation performance (p = 0.012, Student t-test). It is
also worthy to mention that Visthesia group exhibited
less intense pain than patients in Viscoat group (p <
0.0001, MWW test).
There was a statistically significant difference in CCT
between the two groups at the three time points of the
Table 2 Demographic characteristics and intraoperative data of the two groups
Viscoat group (n = 41) Visthesia group (n = 36) p
Continuous variables mean ± SD mean ± SD
Age (years) 77.6 ± 8.4 77.7 ± 8.7 0.949
BCVA preoperatively (LogMAR) 0.42 ± 0.22 0.41 ± 0.25 0.844
ECC preoperatively (cells/mm
2) 2424.9 ± 449.03 2307.6 ± 382.63 0.225
CCT preoperatively (μm) 554.9 ± 43.75 560.2 ± 42.84 0.591
Macular thickness preoperatively (μm) 156.9 ± 23.33 159.2 ± 26.56 0.684
U/S duration intraoperatively (min) 0.83 ± 0.70 0.66 ± 0.38 0.483
Total operating time (min) 15.90 ± 2.97 14.43 ± 1.85 0.012
Intraoperative pain (VAS score) 3.27 ± 0.81 1.00 ± 0.76 <0.0001
Categorical and ordinal variables NN
Sex
Male/Female 15/26 11/25 0.577
Operated eye
Right/Left 20/21 19/17 0.726
BCVA = best corrected visual acuity; ECC = endothelial cell count; CCT = central corneal thickness; U/S = ultrasound; VAS = visual analog scale
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± 45.07 vs. 613.6 ± 41.36 on day 3, p = 0.012, MWW;
568.9 ± 44.96 vs. 593.4 ± 43.08 on day 15, p = 0.009,
MWW; 555.1 ± 42.53 vs.579.3 ± 42.70 on day 28, p =
0.008, MWW, Figure 1).
Respectively, there was a statistically significant differ-
ence in ECC between the two groups at the three time
points of the follow-up (for Viscoat and Visthesia
respectively: 2122.6 ± 526.1 vs. 1891.7 ± 385.5 on post-
operative day 3, p = 0.011, MWW; 2321.9 ± 468.1 vs.
2035.3 ± 376.9 on postoperative day 15, p = 0.006,
MWW; 2395.9 ± 451.2 vs. 2090.6 ± 384.7 on postopera-
tive day 28, p = 0.003, MWW, Figure 2). Preoperative
mean endothelial cell density was 2425 cells/mm
2 in the
Viscoat group and 2308 cells/mm
2 in the Visthesia
g r o u p( p=0 . 2 2 5 ,M W W ) .N o t i c e a b l y ,t h ed e n s i t y
decreased by 29 cells/mm
2 (a 1.2% loss) in the Viscoat
group and by 217 cells/mm
2 (a 9.6% loss) in the Visthe-
sia group 28 days postoperatively (p < 0.0001), as it is
illustrated in Table 3.
Visthesia group differed significantly in comparison
with Viscoat group regarding macular thickness, at the
late time point of the follow-up (for Viscoat and Visthe-
sia respectively: 169.8 ± 19.9 vs. 174.6 ± 23.5 on post-
operative day 3, p = 0.330, MWW; 158.3 ± 17.7 vs.
169.5 ± 22.9 on postoperative day 15, p = 0.018, MWW;
152.0 ± 16.3 vs. 166.3 ± 21.4 on postoperative day 28, p
= 0.002, MWW, Figure 3).
BCVA (logMAR) did not differ between the two
groups (for Viscoat and Visthesia respectively: 0.24 ±
0.24 vs. 0.26 ± 0.37 on postoperative day 3, p = 0.238,
MWW; 0.07 ± 0.09 vs. 0.05 ± 0.08 on day postopera-
tive day 15, p = 0.041, MWW; 0.0014 ± 0.0078 vs.
0.001 ± 0.0083 on postoperative day 28, p = 0.926,
MWW, Figure 4).
Worthy of note, intraoperative pain was not associated
with operation time in either groups (Spearman’sr h o=
0.185, p = 0.247 in the Viscoat group and Spearman’s
rho = 0.176, p = 0.304 in the Visthesia group).
Discussion
The principle message of our study is that Viscoat pro-
vides better protection to corneal endothelium in compari-
son with Visthesia during uneventful phacoemulsification
cataract surgery. This is apparent, because Visthesia
caused a larger endothelial cell loss, as well as more cor-
neal edema than Viscoat. Nevertheless, the two OVDs had
n os i g n i f i c a n t l yd i f f e r e n c ea sf a ra st h eB C V Aa c q u i r e d
postoperatively.
The main reason for using OVDs in cataract surgery
is to prevent damage of the corneal endothelium. Dis-
persive OVDs, such as Viscoat, are considered to protect
the endothelium better than cohesive OVDs, because of
their lower specific surface properties [2]. However, they
need longer aspiration time to be removed from the
anterior chamber and it may damage the corneal
endothelium in this way [2-9,15]. In our study, there
was a significant difference in the duration of the opera-
tion, noting that Viscoat group needed more time for
the surgery, although the duration of the ultrasound
application did not differ between the two groups. On
Figure 1 Central corneal thickness (mean ± standard error, μm)
preoperatively and on postoperative days 3, 15 and 28 in
Viscoat group (dots) and Visthesia group (triangles).
Figure 2 Endothelial cell count (mean ± standard error, cells/
mm
2) preoperatively and on postoperative days 3, 15, 28 in
Viscoat group (dots) and Visthesia group (triangles).
Table 3 Endothelial cell density over time
Time period Viscoat group Visthesia
group
p
Preoperative ECC (cells/mm
2) 2424.9 ± 449.03 2307.6 ± 382.63 0.225
Postoperative day 28 ECC
(cells/mm
2)
2395.9 ± 451.2 2090.6 ± 384.7 0.003
Decrease in the ECC (%) -1.24 ± 2.04 -9.60 ± 3.86 <0.0001
ECC = endothelial count cells
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effective in keeping a deep anterior chamber than the
dispersive one. They also tend to escape from the ante-
rior chamber, leaving endothelial cells without protec-
tion [6,16]. In addition to this, there are studies showing
that Visthesia could be harmful to the corneal endothe-
lium [17,18].
The damage of the corneal endothelium can be evalu-
ated by measuring the endothelial cell decrease after
surgery [9]. Adult human corneal endothelium is con-
sidered a non-replicative tissue and there is a natural
decrease in endothelial cell density by age [19]. Disper-
sive OVDs are expected to cause less endothelial cell
loss, as they protect better the corneal endothelium.
This is in line with Glasser et al. who observed less
endothelial cell loss in eyes receiving Viscoat than in
those receiving 1% sodium hyaluronate (Healon
® OVD,
AMO), a cohesive OVD [20]. On the contrary, Holzer et
al. suggested that 2.3% sodium hyaluronate (Healon
® 5,
OVD, AMO) had lower mean endothelial cell loss in
comparison with Viscoat, while Lane et al. found similar
amounts of endothelial cell loss in eyes receiving cohe-
sive and dispersive OVDs [5,21]. In our study, there is a
statistically significant difference in endothelial cell loss
between the two groups. The mean endothelial cell loss
was for Visthesia 9.6% and for Viscoat 1.2%. Of note,
the endothelial cell decreases for several OVDs are
between 0.3% and 20.32%. Our results are comparable
with those in other investigations published in the litera-
ture [3,5-9,16,20-25].
Another sign of functional damage of the corneal
endothelium is the CCT. Corneal thickness increases
when the pump and barrier functions of the endothe-
lium are damaged, affecting the clarity of the cornea
[24,26]. If there is a certain decrease in endothelial cells
and an increase in corneal thickness, corneal edema
appears [6]. There are several studies reporting an acute
reversible increase in CCT after phacoemulsification cat-
aract surgery [3,15,24,27]. Kiss et al. found no signifi-
cantly difference in corneal edema and endothelial cell
loss, when comparing Viscoat and 2% hydroxypropyl
methylcellulose (Ocucoat
®, Bausch & Lomb) [24]. On
the contrary, Koch et al. observed better endothelial
protection with Viscoat vs. Healon [16], in parallel with
Storr-Paulsen et al. who stated that dispersive OVDs are
more protective for the corneal endothelium [6]. The
latter is in accordance with our results showing that
Viscoat differ significantly in CCT and endothelial cell
loss in comparison with Visthesia, supporting the fact
that Viscoat provides more protection to the corneal
endothelium. Concerning Visthesia, in line with our
results, Valimaki et al. noted that Visthesia presented an
increased risk for postoperative corneal edema [13].
Furthermore, an interesting finding of our study was
that macular thickness was significantly higher in
Visthesia group than in Viscoat one on postoperative
day 28. This is the first study examining the possible
effect of OVDs on macular thickness. It is well estab-
lished that foveal thickness could be increased post-
operatively [28,29]. However, according to Johansson et
al., intracameral lidocaine did not produce more pro-
nounced macular edema than other methods of anesthe-
sia [30]. In our study, there was a little increase (4%) in
macular thickness in Visthesia group, while in Viscoat
group macular thickness was lower postoperatively (3%
decrease). Nevertheless, macular thickness of both
groups was normal and cystoid macular edema was not
developed, except for one patient in Visthesia group
who was excluded.
Noticeably, postoperative BCVA did not differ
between the two groups, although there were differences
Figure 3 Macular thickness (mean ± standard error, μm)
preoperatively and on postoperative days 3, 15 and 28 in
Viscoat group (dots) and Visthesia group (triangles).
Figure 4 BCVA (mean ± standard error, logMAR)
preoperatively and on postoperative days 3, 15 and 28 in
Viscoat group (dots) and Visthesia group (triangles).
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nation is that the aforementioned parameters reached
normal ranges postoperatively in both groups and there-
fore did not affect negatively BCVA. It is worthy to say
that all patients presented with excellent BCVA on post-
operative day 28, suggesting that uneventful phacoemul-
sification cataract surgery is beneficial for patients’
visual acuity.
Concerning intraoperative pain, Visthesia group exhib-
ited less intense pain than patients in Viscoat group.
Combining an OVD with an anaesthetic agent is very
important, as this viscoelastic concept provides comfort
to both patients and surgeons during the operation
[9,31]. However, lidocaine hydrochloride may be the
responsible agent for the differences in ECC, CCT and
macular thickness between the two groups. Neverthe-
less, experimental works in the rabbits showed that
intracameral use of lidocaine 2% induces few ultrastruc-
ture alterations in the corneal endothelial cells [32].
Also clinical studies demonstrated that intracameral
lidocaine does not induce significant macular edema
than the standard regimen of topical mydriatics plus
intracameral lidocaine [30].
A meaningful limitation of this study pertains to the
underlying nature of the comparison presented herein.
Specifically, we compared two OVDs with different phy-
sicochemical and rheological properties, one with and
the other without lidocaine. Therefore, we have reached
conclusions encompassing potential confounders i.e.,
between the presence of lidocaine in Visthesia and the
different properties of the two OVDs. In addition, the
possibility of recall bias interfering with intraocular pain
may not be ruled out, but has essentially been mini-
mized as patients were asked to rate their intraoperative
pain immediately after surgery.
Conclusions
In conclusion, our study suggests that Viscoat is more
safe and protective for the corneal endothelium during
uneventful phacoemulsification cataract surgery, while
Visthesia is in superior position regarding intraoperative
pain. Patients of both groups acquired excellent visual
acuity postoperative, pointing on the value of cataract
surgery when necessary. Finally, this is the first study
comparing OVDs in terms of macular thickness, finding
that Visthesia cause a greater increase in macular thick-
ness postoperatively than Viscoat, although it reaches
normal ranges in both groups.
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